IVA - Inventiva Sa logo

IVA

Inventiva Sa

Inventiva S.A. develops oral small molecule therapies primarily for metabolic dysfunction-associated steatohepatitis and mucopolysaccharidoses. Its key products include Lanifibranor, in Phase 3 trials, and Odiparcil for treating specific genetic disorders.

⚕️ Healthcare NASDAQ Listed 2020 € EUR
$1,000 invested 5 years ago $436today

Score Overview

1 Year
Score
Net Growth-95.48%
Net TrendShrank
Net Income Consistency
Rev Growth144.83%
Rev TrendGrew
Revenue Consistency
5 Years
Score2.0
Net Growth-11x
Net TrendNever
Net Income Consistency
Rev Growth161.70%
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-19x
Net TrendNever
Net Income Consistency
Rev Growth29x
Rev Trend67%
Revenue Consistency

See the full market ranking →

Inventiva Sa fundamental performance

Between 2020 and 2025, revenue grew from € 372K to € 4M and net income went from -€ 31M to -€ 340M. Revenue increased in 3 of those 5 years; net income in 0.

Inventiva Sa currently holds a 5-year HDB Score of 2.0 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 4.68
1 Year2025-08-12
$ 3.6727.52%
5 Years2021-08-12
$ 10.73-56.40%
All Time2020-07-10
$ 13.42-65.13%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026€ 10M-€ 664M€ 99M
2025€ 4M-€ 340M€ 99M
2024€ 9M-€ 184M€ 96M
2023€ 17M-€ 110M€ 27M
2022€ 12M-€ 54M€ 87M
2021€ 4M-€ 49M€ 86M
IPO2020€ 372K-€ 31M€ 113M

Explore beyond IVA

You're looking at Inventiva Sa. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies